目的 探討伸筋草生物堿對完全弗氏佐劑（CFA）誘導(dǎo)大鼠關(guān)節(jié)炎的治療作用及機制。方法 健康SD大鼠48只，隨機分為6組，每組8只，即對照組、模型組、依托考昔片（陽性藥，1 mg/kg）組及伸筋草生物堿低、中、高劑量（30、60、120 mg/kg）組，除對照組外，其余40只大鼠sc 0.1 mL CFA造模，致炎15 d后，連續(xù)ig給藥30 d。測定大鼠足趾腫脹率、HE染色后觀察造模測踝關(guān)節(jié)滑膜病理改變；致炎45 d，ELISA法測定血清中白介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）水平。結(jié)果 與模型組比較，依托考昔片及伸筋草生物堿低、中、高劑量組足趾腫脹率均顯著下降（P<0.05、0.01）；中、高劑量伸筋草生物堿明顯改善滑膜細(xì)胞、巨噬細(xì)胞、纖維細(xì)胞增生與炎癥細(xì)胞浸潤；與模型組比較，依托考昔片及伸筋草生物堿高劑量組大鼠血清TNF-α水平顯著下降（P<0.05），依托考昔片及伸筋草生物堿各劑量組IL-1β水平均顯著降低（P<0.01）。結(jié)論 伸筋草生物堿顯著抑制CFA誘導(dǎo)關(guān)節(jié)炎大鼠關(guān)節(jié)腫脹，改善大鼠踝關(guān)節(jié)滑膜病變，其作用機制可能與降低體內(nèi)IL-1β、TNF-α水平有關(guān)。

Objective To explore the therapeutic effect and mechanism of shenjincao alkaloids (SJA) on arthritis induced by complete freund's adjuvant (CFA) in rats. Methods 48 healthy SD rats were randomly divided into 6 groups, 8 in each group, namely control group, model group, Etoncoxib (Positive drug, 1 mg/kg) group, and low-,medium-and high-dose (30, 60, and 120 mg/kg) SJA groups,40 healthy SD rats were injected with 0.1mL CFA in addition to control group.The swelling rate of rat toes was measured and the pathological changes of ankle synovial membrane were observed.For 45 days, ELISA assay was used to determine the level of serum IL-1β and TNF-α. Results Compared with model group, the toe swelling rate of each group was significantly decreased (P<0.05 and 0.01), and the levels of synovial cells, macrophages, fibroblast proliferation and inflammatory cell infiltration were also significantly decreased in medium and high doses of SJA groups. Compared with model group, the serum TNF-α level of rats in Etoncoxib and high-dose group of SJA decreased significantly (P<0.05), and the IL-1β level of rats in Etoncoxib and each dose group of SJA decreased significantly (P<0.01). Conclusion SJA can inhibit the CFA induced joint swelling in arthritis rats, improve ankle synovial lesions in rats, and have therapeutic effects on adjuvant arthritis rats. The mechanism may be related to decreasing the level of IL-1β and TNF-α in vivo.

上海市教委預(yù)算內(nèi)項目（2015YSN46）；岳陽中西醫(yī)結(jié)合醫(yī)院院級基金（2018YJ06）